Skip to content

Effectiveness and Safety of Angongniuhuang Pill on Restoring Consciousness for Patients Who Have Suffered From a Stroke

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00817609
Enrollment
60
Registered
2009-01-06
Start date
Unknown
Completion date
Unknown
Last updated
2010-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke, Stroke

Keywords

Angongniuhuang Pill, consciousness level of patients who suffered from a stroke

Brief summary

This study will determine if Angongniuhuang Pill (Composed of Niuhuang, Yujin, Xijiao, Huangqin, Huanglian, Xionghuang, Zhizi, Zhusha, Bingpian, Shexiang, and Zhenzhu) will have a better effect in restoring consciousness for patients who have suffered from an acute ischemic stroke. The study is designed to look at both consciousness level and overall recovery and recovery of motor function, for example muscle strength and coordination.

Interventions

7 days of Angongniuhuang Pill

DRUGplacebo

7 days of placebo

Sponsors

Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Occurrence of an acute ischemic stroke (between 9 and 72 h after onset) with * A score of not higher than 12 of Glasgow Coma Scale (GCS) * Patient age of between 18 and 80 years. * Patients or their representatives voluntarily take part in this study and signed the informed consent

Exclusion criteria

* Transient Ischemic attack(TIA), cerebral hemorrhage, subarachnoid hemorrhage * Ischemic stroke that needs rt-PA treatment * Subjects who are unlikely to complete taking the investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition. * Pregnant or breast-feeding. * Proven disability by law, such as blindness, deafness, dumb, disturbance of intelligence, mental disorders, limb handicap. * Liable to be allergic (allergic to at lease 2 foods/drugs previously exposed) * Had been participated in other clinical trials during the last 1 month prior to study inclusion.

Design outcomes

Primary

MeasureTime frame
Glasgow Coma Scale (GCS) within 90 days after stroke onset.90 days

Secondary

MeasureTime frame
The percentage of patients of different consciousness level stratified according to the GCS, and the time spent of patients who recovered from coma.90 days
Global disability on modified Rankin scale at 90 days.90 days
NIH stroke scale90 days
Changes in laboratory indexes as safety assessment, including red blood cell(RBC), white blood cell(WBC), platelet(PLT), alanine transarninase(ALT), aspartate transarninase (AST), blood urea nitrogen (BUN), creatinine(Cr) in blood samples; protein, red b14 days

Countries

China

Contacts

Primary ContactDingfang Cai, MD
doctorcn@hotmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026